Glucagon-like peptide-1: difference between revisions
Diff·revision 16 → 17·20:43, 5 Jan 2025
Difference between revision 16 and revision 17 of Glucagon-like peptide-1. 1 line changed; the page grew by 73 bytes.
| Revision 16 — 15:34, 21 Dec 2024 CategoryBot (talk) bot: expand PMID to full citation 9,944 bytes +1,717 | Revision 17 — 20:43, 5 Jan 2025 EmptyingElke (talk) clarify that concentrations differ substantially between assay platforms 10,017 bytes +73 | ||
|---|---|---|---|
| 18 | }} | 18 | }} |
| 19 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} | 19 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} |
| + | 20 | {{technical|date=March 2026|talk=Readability of the signalling section}} | |
| 20 | 21 | ||
| 21 | '''Glucagon-like peptide-1''' ('''GLP-1''') is a 30- or 31-residue [[peptide]] hormone released from [[Enteroendocrine L cell|enteroendocrine L cells]] of the distal small intestine and colon in response to nutrient ingestion. It is one of the two principal [[Incretin effect|incretin]] hormones, the other being [[Glucose-dependent insulinotropic polypeptide]] (GIP).{{r|holst2007}} | 22 | '''Glucagon-like peptide-1''' ('''GLP-1''') is a 30- or 31-residue [[peptide]] hormone released from [[Enteroendocrine L cell|enteroendocrine L cells]] of the distal small intestine and colon in response to nutrient ingestion. It is one of the two principal [[Incretin effect|incretin]] hormones, the other being [[Glucose-dependent insulinotropic polypeptide]] (GIP).{{r|holst2007}} |